← FDA DRUG APPROVALS

FDA ANDA · ANDA202333

SODIUM POLYSTYRENE SULFONATE

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA202333
TYPE
ANDA
ORIGINAL APPROVAL
2014-03-19
LATEST ACTION
2020-02-25
ROUTE
ORAL, ORAL, RECTAL
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

SODIUM POLYSTYRENE SULFONATEPrescription
SODIUM POLYSTYRENE SULFONATE 453.6GM/BOT · POWDER · ORAL, RECTAL

Approval history

2020-02-25Labeling · Supplement 1 · standardAP
2014-03-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →